Back to Search Start Over

Country ownership as a guiding principle for IA2030: A case study of the measles and rubella elimination programs in Nepal and Nigeria.

Authors :
Wonodi C
Crowcroft N
Bose AS
Oteri J
Momoh J
Hughes G
Shet A
Pradhan R
Gautam JS
Jean Baptiste AE
Khanal S
Masresha B
Linstrand A
Source :
Vaccine [Vaccine] 2024 Apr 08; Vol. 42 Suppl 1, pp. S107-S117. Date of Electronic Publication: 2023 Oct 13.
Publication Year :
2024

Abstract

Country-owned, as opposed to donor-driven, is a principle within the development sector that recognizes the centrality of countries' leadership, systems, and resources in executing programs and achieving sustainable development. In alignment with this notion, the Immunization Agenda 2030 was developed with country ownership as one of four core principles of the ambitious ten-year plan. This means that the success of immunization programs, including those with eradication and elimination goals such as polio, measles, and rubella, and those with broader equity goals to "leave no one behind" on immunization, would be largely driven by country systems. In this paper we deconstruct country ownership into five operational principles: commitment, coordination, capacity, community participation, and accountability. Through this lens, we illustrate how two countries, Nepal and Nigeria, have exemplified country ownership in their measles and rubella elimination programs and we infer the ways in which country ownership drives system performance and sustains program efforts.<br />Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024 World Health Organization. Published by Elsevier Ltd.. All rights reserved.)

Details

Language :
English
ISSN :
1873-2518
Volume :
42 Suppl 1
Database :
MEDLINE
Journal :
Vaccine
Publication Type :
Academic Journal
Accession number :
37838480
Full Text :
https://doi.org/10.1016/j.vaccine.2023.09.048